Diagnosis of prostate cancer: State of the art;Diagnosi del carcinoma prostatico: Stato dell'arte

Minerva Urologica e Nefrologica

Volumn 56, Issue 2, 2004, Pages 123-145

  Roscigno, M ^a   Scattoni, V ^a   Bertini, R ^a   Pasta, A ^a   Montorsi, F ^a   Rigatti, P ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Biopsy; Prostate specific antigen; Prostatic neoplasms, diagnosis; Ultrasonography

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AWARENESS; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGING SYSTEM; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PROSTATE BIOPSY; PROSTATE CANCER; RECTUM; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

BIOPSY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 3843139312     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Landis SH, Murray T, Golden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: result of a multicenter clinical trial of 6630 men. J Urol 1994;151: 1283-90.
3. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL et al. Comparison of prostate-specific antigen concentration versus prostate-specific antigen density in the early detection of prostate cancer. Receiver operating characteristic curves. J Urol 1994; 152:2031-6.
4. Littrup PJ, Lee F, Mettlin C. Prostate cancer screening: current trends and future implications. CA Cancer J Clin 1992;42:198-211.
5. Carter HB, Parting AW. Diagnosis and staging of prostate cancer. In: Walsh PC, Retik AB, Darracott Vaughan E, Darracott Vaughan E editors. Campbell's urology. Philadelphia: Saunders; 1998.p.2519-33.
6. Myrtle J, Ivor L. Measurement of prostate-specific antigen (PSA) in serum by a two-site immunometric method (Hybritech Tandem-R/ Tandem-E PSA). In: Catalona WJ editor. Clinical aspects of prostate cancer. New York: Elsevier; 1989.p.161-71.
7. Brawler M, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 1993;150:106-9.
8. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.
9. Ellis WJ, Etzioni R, Vessella RL, Hu C, Goodman GE. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. J Urol 2001;166:93-9.
10. Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J Urol 1992;148:83-6.
11. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993;42:276-82.
12. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992;147:810-4.
13. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995;154:407-13.
14. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997;24:283-91.
15. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery: what we have learned and where we are going. J Urol 1999;162:293-306.
16. Reissigl A, Pointner J, Horninger W, Ennemoser O, Strasser H, Klocker H et al. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology 1995;46:662-5.
17. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.
18. Nishiya M, Miller GJ, Lookner DH, Crawford ED. Prostate-specific antigen density in patients with histologically prove prostate carcinoma. Cancer 1994;74: 3002-9.
19. Brawer MK, Aramburu EA, Chen GL, Preston SD, Ellis W. The inability of prostate specific antigen to enhance the predictive value of PSA in the diagnosis of prostatic carcinoma. J Urol 1993;150:369-73.
20. Kalish J, Cooner WH, Graham Jr SD. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994;43:601-6.
21. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52: 3323-8.
22. Carter HB, Pearson JD. Evaluation of changes in PSA in the management of men with prostate cancer. Semin Oncol 1994;21:554-9.
23. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
24. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. Prostate-specific antigen density (PSAD): pole in patient evaluation and management. Urol Clin North Am 1993;20:653-63.
25. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate-specific antigen in men 60 years old or older. J Urol 1995;153:1160-3.
26. Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J Urol 1996;155:1336-9.
27. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A et al. Cost-effective prostate cancer detection: reduction of lowyield biopsies. Cancer 1994;74:3146-58.
28. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate-specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344: 1594-8.
29. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alfa 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
30. Catalona WJ, Parti AW, Slavin KM, Drawer MK, Flanigan RC, Patel A et al. Use of percentage of free prostate-specific antigen to enhance differentation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
31. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL et al. Evaluation of percentage of the serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
32. Akdas A, Cevik I, Turkeri L, Dalaman G, Emerk K. The role of free prostate-specific antigen in the diagnosis of prostate cancer. Br J Urol 1997;76:920-3.
33. Catalona WJ. Single and serial measurement of serum prostate-specific antigen as a screenig test for early prostate cancer. J Urol 1992;147:450A.
34. Cooner WH, Mosley BR, Rutheford Jr CL, Beard JH, Pond HS, Terry WJ et al. Prostate cancer detection in a clinical urological practice ultrasonography. J Urol 1990;143:1146-52; discussion 1152-54.
35. Ellis WJ, Chetner MP, Preston SD, Brawer MK. Diagnosis of prostatic carcinoma: the Yield of serum prostate-specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994;152:1520-5.
36. Potter SR, Horniger W, Tinzi M, Bartsch G, Partin AW. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001;57:1100-4.
37. Sedelaar M, Vijverberg P, De Reijke T, de la Rosette J, Kil P, Braeckman J et al. Transrectal ultrasound in the diagnosis of prostate cancer: state of the art and prospectives. Eur Urol 2001;40:275-84.
38. Partin AW, Stutzman RE. Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination and transrectal ultrasound and prostate biopsy. Urol Clin N Am 1998;25:581-9.
39. Sedelaar JP, van Roermund JG, van Leenders GL, Hulsbergen-van de Kaa CA, Wijkstra H, de la Rosette JJ. Three-dimensional grayscale ultrasound: evaluation of prostate cancer compared with benign prostatic hyperplasia. Urology 2001;57:914-20.
40. Marie L, Merzoug V, Anidjar M, Hoffman P, Desgrandchamp F, Cortesse A, et al. Three-dimensional transrectal ultrasonography increase prostate biopsies accuracy. Eur Urol 1999;35:1.
41. Garg S, Fording B, Chadwick D, Robinson MC, Hamdy FC. Staging of prostate cancer using 3-dimensional transrectal ultrasound images: a pilot study. J Urol 1999;162:1318-21.
42. Hamper UM, Trapanotto V, Dejong MR, Shheth S, Caskey CI. Three-dimensional US of the prostate: early experience. Radiology 1999;212:719-23.
43. Halpern EJ, Strup SE. Using grayscale and color and power Doppler sonography to detect prostatic cancer. AIR Am J Roentgenol 2000;174:623-7.
44. Okihara K, Kojima M, Nakanouchi T, Okada K, Miki T. Transrectal power poppler imaging in the detection of prostate cancer. BJU Int 2000;85:1053-7.
45. Burns PN, Hilpert P, Goldberg BB. Intravenous contrast agent for ultrasound Doppler: in vivo measurement of small vessel dose response. Eng Med Biol Soc 1990; 12:322.
46. Bogers Ha, Sedelaar JPM, Beerlage HP, de la Rosette JJMCH, Debruyne FMJ, Wijkstra H et al. Contrast-enhanced three dimensional power Doppler angiography of the human prostate: correlation with biopsy outcome. Urology 1999;54:97-104.
47. Halpern EJ, Rosemberg M, Gomella LG. Prostate cancer: contrast-enhanced us for detection. Radiology 2001;219:219-25.
48. Chomas JE, Dajton P, Allen J, Morgan K, Ferrara KW. Mechanisme of contrast agent destruction. IEEE Trans Ultrason Ferroelectr Freq Control 2001;48:232-48.
49. Tiemann K, Pohl C, Schlosser T, Goenechea J, Bruce M, Veltman C et al. Stimulated acoustic emission: pseudo-doppler shifts seen during the destruction of non-moving microbubbles. Ultrasound Med Biol 2000;26: 1161-7.
50. Dayton PA, Morgan KE, Klibanov AL, Brandenburger GH, Ferrara KW. Optical and acoustical observation of the effects of ultrasound on contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control 1999;46:220-32.
51. Halpern EJ, Verkh L, Forsberg F, Gomella LG, Mattrey RF, Golberg BB. Initial experience with contrast-enhanced sonography of the prostate. AJR Am J Roentgenol 2000;74:1575-80.
52. Hodge KK, MecNeal JE, Terris Mk, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-5.
53. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate understimated the presence of cancer. Urology 1997;50:562-6.
54. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-4.
55. Ellis WJ, Brower MK. Repeat prostate needle biopsy: who needs it? J Urol 1995;153:1496-8.
56. Melchior SW, Brawler MK. Role of transrectal ultrasound and prostate biopsy. J Clin Ultrasound 1996;24: 463-71.
57. Langer JE. The current role of transrectal ultrasonography in the evaluation of prostate carcinoma. Semin Roentgenol 1999;34:284-94.
58. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12.
59. Applewhite JC, Matlaga BR, McCullough DL, Hall CM. Transrectal ultrasound and biopsy in the early diagnosis of prostate Cancer. Cancer Control 2001;8: 141-50.
60. Presti JCJ, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000;163:163-6.
61. Rietbergen JBW, Kranse R, Kirkels WJ, Hoedemaeker F, Schroeder FH. Prostate cancer screening: value of the seventh targeted to visible lesions. J Urol 1997;157:58A.
62. Fleshner NE, O'Sullivan M, Premdass C, Fair WR. Clinical significance of small (less thain 0,2 cm cubici) hypoechoic lesions in men with normal digital rectal examinations and prostate-specific antigen levels of less than 10 ng/ml. Urology 1999;53:356-8.
63. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157: 199-202.
64. Nava L, Montorsi F, Consonni P, Scattoni V, Guazzoni G, Rigatti P. Results of a prospective randomized study comparing 6,12,18 transrectal ultrasound guided sextant biopsies in patients with elevated PSA, normal DRE and normal prostatic ultrasound. J Urol 1997;157 Suppl:59A.
65. Noughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 2000;164:388-92.
66. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM et al. Optimal combinations of systematic and laterally directed biopsies for the detection of prostate cancer. J Urol 2001;165:1554-9.
67. Scattoni V, Zlotta AR, Nava L, Roscigno M, Montorsi F, Rigatti P. Prostatic Transrectal Ultrasound (TRUS) Guided Biopsy Schemes and TRUS Prostatic Lesion-Guided Biopsy. Eur Urol Suppl 2002;1:28-34.
68. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 2000;89:1800-9.
69. Djavan B, Zlotta AR, Ekane S, Remzi M, Kramer G, Roumeguère T et al. Is one set of sexante biopsies enough to rule out prostate cancer? Influence of transition and total prostate cancer yield. Eur Urol 2000; 38:218-24.
70. Terris MK, Pham TQ, Issa MM, Kabalin JN. Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J Urol 1997;157:204-6.
71. Fleshner NE, Fair WR. Indications for transition zone biopsy in the detection of prostatic carcinoma. J Urol 1997;157:556-8.
72. Chang JJ, Shinohara K, Bhargava V, Presti JCJ. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998;160:2111-4.
73. Terris MK, Wallen EM, Stamey TA. Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol Int 1997;59:239-42.
74. Aus G, Bergdahl S, Hugosson J, Lodding p, Pihl CG, Pileblad E. Outcome of the laterally directed sextant biopsies of the prostate in screened males aged 50-66 years. Eur Urol 2001;39:655-6l.
75. Bauer JJ, Zeng J, WeiAr J, Zhang W, Sesterhenn IA, Connelly RR et al. Three-dimensional computer-simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer. Urology 1999;53: 961-7.
76. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000;163:152-7.
77. Babaian RJ. Extended field prostate biopsy enhances cancer detection. Urology 2000;55:453-6.
78. Toi A, Chen ME, Kamoi K, Troncoso PT, Babaian J. New biopsy strategy detects prostate cancers missed by conventional sextant biopsies. J Urol 1999;161 Suppl: 322.
79. Hricak H, Williams RD, Spring DB, Moon KL, Hedgecock MW, Watson RA et al. Anatomy and patology of the male pelvis by magnetic resonance imaging. AJR Am J Roentgenol 1983;141:1101-6.
80. Bezzi M, Kressel HY, Allen KS, Schiebler ML, Altman HG, Wein AJ et al. Prostatic carcinoma: staging with MR imaging at 1,5 T. Radiology 1998;168:339-44.
81. Lovett K, Rifkin MD, McCue PA, Choi H. MR imaging characteristics of noncancerous lesion of the prostate. J Magn Reson Imaging 1992;2:35-9.
82. Perrotti M, Han KR, Epstein RE, Kennedy EC, Rabbani F, Badani K et al. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. J Urol 1999;162:13l4-8.
83. Beyersdorff D, Taupitz M, Winkelmann B, Fisher T, Lenk S, Loening SA et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002;224:701-6.
84. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med 1990;323:621-7.
85. D'Amico AV, Whittington R, Malkowicz B, Schnall M, Schultz D, Cote K et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000;164:759-65.
86. Jager GJ, Severens JL, Thornbury JR, de La Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: should MR imaging be used? A decision analytic approach. Radiology 2000;215:445-51.
87. Jager GJ, Ruijter ET, van de Kaa CA, de La Rosette JJ, Oosterhof GO, Thornbury JR et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopatology. AJR Am J Roentgenol 1996; 166:845-50.
88. Jhaveri F, Klein E. How to explore the patients with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin Urol Oncol 1999;17: 130-4.
89. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-42.
90. Neulander EZ, Soloway MS. Failure after radical prostatectomy. Urology 2003;61:30-6.
91. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ et al. Evaluation of prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence versus distant metastases. Urology 1994;43:649-59.
92. Patel A, Dorey F, Franklin J, DeKernion JB. Recurrence pattern after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158: 1441-5.
93. Pound CR, Christens-Barry OW, Gurganus R, Partin AW, Walsh PC. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 1999;162:1337-40.
94. Öbek C, Neulander E, Sadek S, Soloway M. Is there a role for digital examination in the follow-up of patients after radical prostatectomy? J Urol 1999;162:762-4.
95. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 2001; 219:432-9.
96. Scattoni V, Roscigno M, Raber M, Consonni P, Da Pozzo L, Rigatti P. Biopsy of the vesico-urethral anastomosis after radical prostatectomy: when and how. Eur Urol Suppl 2002;1:89-95.
97. Goldenberg SL, Carter M, Dashefsky S, Cooperberg PL. Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol 1992;147:1307-9.
98. Lightner DJ, Lange PH, Reddy PK, Moore L. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 1990;144:921-6.
99. Scattoni V, Roscigno M, Raber M, Montorsi F, Da Pozzo L, Guazzoni G et al. Multiple vesico-urethral biopsies following a radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003;44:407-14.
100. Raj GV, Partin AW, Polascik TJ. Clinical utility of Indium 111-Capromab Pendetite Immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002;94:987-96.
101. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997;27:94-106.
102. Picchio M, Messa C, Landoni C, Gianolli S, Sironi S, Brioschi M et al. Value of [11C]Choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337-40.